|
|
Marcelo Páez-Pereda, Damian Kovalovsky, Ursula Hopfner, Marily Theodoropoulou, Uberto Pagotto, Eberhard Uhl, Marco Losa, Johanna Stalla, Yvonne Grübler, Cristina Missale, Eduardo Arzt, Günter K. Stalla
J Clin Invest. 2001;
108(8):1123
doi:10.1172/JCI11098
Abstract |
Full text
| PDF

C
ushing syndrome is caused by an excess of adrenocorticotropic hormone (ACTH) production by neuroendocrine tumors, which subsequently results in chronic glucocorticoid excess. We found that retinoic acid inhibits the transcriptional activity of AP-1 and the orphan receptors Nur77 and Nurr1 in ACTH-secreting tumor cells. Retinoic acid treatment resulted in reduced pro-opiomelanocortin transcription and ACTH production. ACTH inhibition was also observed in human pituitary ACTH-secreting tumor cells and a small-cell lung cancer cell line, but not in normal cells. This correlated with the expression of the orphan receptor COUP-TFI, which was found in normal corticotrophs but not in pituitary Cushing tumors. COUP-TFI expression in ACTH-secreting tumor cells blocked retinoic acid action. Retinoic acid also inhibited cell proliferation and, after prolonged treatment, increased caspase-3 activity and induced cell death in ACTH-secreting cells. In adrenal cortex cells, retinoic acid inhibited corticosterone production and cell proliferation. The antiproliferative action and the inhibition of ACTH and corticosterone produced by retinoic acid were confirmed in vivo in experimental ACTH-secreting tumors in nude mice. Thus, we conclude that the effects of retinoic acid combine in vivo to reverse the endocrine alterations and symptoms observed in experimental Cushing syndrome.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(14)
| Title and authors |
Publication |
Year |
Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways
Paraskevi Xekouki, Monalisa Azevedo, Constantine A Stratakis
|
Expert Rev Endocrinol Metab
|
2010 |
Key signaling molecules in pituitary tumors
Cristiana Pistol Tanase, Monica Neagu, Radu Albulescu
|
Expert Rev Mol Diagn
|
2009 |
Pituitary-directed medical treatment of Cushing’s disease
Giorgio Arnaldi, Marina Cardinaletti, Laura Trementino, Giacomo Tirabassi, Marco Boscaro
|
Expert Rev Endocrinol Metab
|
2009 |
Pituitary-targeted medical therapy of Cushing's disease
Krystallenia I Alexandraki, Ashley B Grossman
|
Expert Opin. Investig. Drugs
|
2008 |
Pituitary Action of Cytokines: Focus on BMP-4 and gp130 Family
Damiana Giacomini, Matías Acuña, Juan Gerez, Alberto Carbia Nagashima, Susana Silberstein, Marcelo Páez-Pereda, Marta Labeur, Marily Theodoropoulou, Ulrich Renner, Günter K. Stalla, Eduardo Arzt
|
Neuroendocrinology
|
2007 |
Endocrine clinical update: Where are we in the therapeutic management of pituitary-dependent hypercortisolism?
Karen R. Mullan, A. Brew Atkinson
|
Clinical Endocrinology
|
2007 |
Advances in medical treatment of Cushing’s disease
Giorgio Arnaldi, Marina Cardinaletti, Marco Boscaro
|
Expert Rev Endocrinol Metab
|
2007 |
Novel therapeutic directions in Cushing’s syndrome
Andrew Levy
|
Expert Rev Endocrinol Metab
|
2006 |
Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease
Francesca Pecori Giraldi, Carla Scaroni, Emanuela Arvat, Martina Martin, Roberta Giordano, Nora Albiger, Adriana A. S. Leao, Andreea Picu, Franco Mantero, Francesco Cavagnini
|
Clinical Endocrinology
|
2006 |
The Nelson's syndrome... revisited
Guillaume Assié, Hélène Bahurel, Jérôme Bertherat, Michèle Kujas, Paul Legmann, Xavier Bertagna
|
Pituitary
|
2005 |
|